Do Kim
Stock Analyst at Piper Sandler
(2.06)
# 2,928
Out of 4,945 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $42.85 | +47.02% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $18.23 | +152.33% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $390.30 | -24.16% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $119.02 | -5.90% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $19.45 | +347.30% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $3.10 | +641.94% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $37.89 | -47.22% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $5.35 | +703.74% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $38.47 | -16.82% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $4.50 | +388.89% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $32.29 | -41.16% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.76 | +479.71% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $442.73 | -58.21% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $6.85 | +13,038.69% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $65.54 | -46.60% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.07 | +1,769.16% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $42.85
Upside: +47.02%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $18.23
Upside: +152.33%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $390.30
Upside: -24.16%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $119.02
Upside: -5.90%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $19.45
Upside: +347.30%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $3.10
Upside: +641.94%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $37.89
Upside: -47.22%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $5.35
Upside: +703.74%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $38.47
Upside: -16.82%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $4.50
Upside: +388.89%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $32.29
Upside: -41.16%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.76
Upside: +479.71%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $442.73
Upside: -58.21%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $6.85
Upside: +13,038.69%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $65.54
Upside: -46.60%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.07
Upside: +1,769.16%